Method Of Treating Silicosis And Other Occupational Lung Diseases
Background:
The National Cancer Institute's Laboratory of Experimental
Immunology is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate, or commercialize methods of treating silicosis and other
occupational lung diseases
The inhalation of dust containing crystalline silica particles
causes silicosis, an incurable lung disease that progresses even
after dust exposure ceases. Over a million US workers are exposed
to silica dust annually, and thousands worldwide die each year from
silicosis. The pulmonary inflammation caused by silica inhalation
is characterized by a cellular infiltrate and the accumulation of
chemokines, cytokines, and Reactive Oxygen Species (ROS) in
bronchoalveolar lavage fluid.
Macrophages are the predominant immune cell type present in
alveolar spaces. The uptake of silica particles by macrophages
triggers the production of ROS (including hydrogen peroxide) via
the oxidative stress pathway, which in turn contributes to
pulmonary damage and macrophage death.
Technology:
One strategy for limiting the production of pro-inflammatory
cytokines and ROS after silica exposure involves treatment with
"suppressive" oligonucleotides (ODN). Suppressive ODN express
motifs based on the repetitive TTAGGG hexamers present at high
frequency in the telomeric ends of self DNA.
This invention describes methods for treating, preventing, or
reducing the risk of developing occupational lung diseases using
ODN treatment. Preclinical in vivo studies show that
pre-treatment with suppressive ODN reduces silica-dependent
pulmonary inflammation. Preclinical in vivo studies also
showed that treatment with suppressive ODN also reduced disease
severity and improved the survival of mice exposed to silica.
Further R&D Needed:
- Develop a mouse model to examine whether suppressive ODN
prevent silica-induced lung cancer
- Establish the utility of suppressive ODN in the
prevention/treatment of acute and chronic diseases caused by
various pulmonary irritants, including but not limited to asbestos
and beryllium
R&D Status: Pre-clinical discovery.
IP Status: U.S. Provisional
Application No. 61/055,102 filed 21 May 2008
Value Proposition:
- AODN-based therapeutics for the treatment of silicosis
Contact Information:
John D. Hewes, Ph.D.
NCI Technology Transfer Center
Tel.: 301-435-3121
Email: hewesj@mail.nih.gov
Please reference advertisement #805
Revised 1/13/2008